Meropenem 1g powder for solution for injection vials
Requires a prescription from a doctor or prescriber
Meropenem is a broad-spectrum carbapenem antibiotic.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Meropenem
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Meropenem
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Meropenem
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
13 branded products available
MHRA licensed products
View all licensed products for Meropenem on the MHRA register
Meronem 1g powder for solution for injection vials
Meropenem 1g powder for solution for injection vials
Meropenem 1g powder for solution for injection vials
Meropenem 1g powder for solution for injection vials
Meropenem 1g powder for solution for injection vials
Meropenem 1g powder for solution for injection vials
Meropenem 1g powder for solution for injection vials
Meropenem 1g powder for solution for injection vials
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
3 gram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(12)
Antimicrobial prescribing: meropenem with vaborbactam (ES21)
Antimicrobial prescribing: ceftolozane with tazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia (ES22)
Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults (ES40)
Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)
Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (AMR1)
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)
Cellulitis and erysipelas: antimicrobial prescribing (NG141)
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Pneumonia: diagnosis and management (NG250)
Xpert Carba-R to identify people carrying carbapenemase-producing organisms (MIB52)
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 19 · Randomised trials: 21 · 2012–2026
Showing the 50 most relevant studies, sorted by most relevant.
R. Wunderink, E. Giamarellos‐Bourboulis, G. Rahav, et al.
Infectious Diseases and Therapy, 2018
R. Wunderink, Y. Matsunaga, M. Ariyasu, et al.
The Lancet. Infectious diseases, 2020
A. Torres, N. Zhong, J. Pachl, et al.
The Lancet. Infectious diseases, 2017
K. Kaye, T. Bhowmick, S. Metallidis, et al.
JAMA, 2018
M. Kollef, Martin Novác̆ek, Ülo Kivistik, et al.
The Lancet. Infectious diseases, 2019
J. Solomkin, J. Gardovskis, K. Lawrence, et al.
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 2018
P. Harris, P. Tambyah, D. Lye, et al.
JAMA, 2018
M. Paul, G. Daikos, E. Durante-Mangoni, et al.
The Lancet. Infectious diseases, 2018
G. Zhanel, Courtney K. Lawrence, H. Adam, et al.
Drugs, 2017
G. Monti, N. Bradic, Matteo Marzaroli, et al.
JAMA, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
1 hour
Mechanism
The bactericidal activity of meropenem results from the inhibition of cell wall synthesis.
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Half-life
1 hour
Protein binding
2%
Metabolism
Elimination
70%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
In August 2017, a combination antibacterial therapy under the market name vabomere was approved for treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of meropenem and DB12107 and is intravenously admininstered. The treatment aims to resolve infection-related symptoms and achieve negative urine culture, where the infections are proven or strongly suspected to be caused by susceptible bacteria.
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 781 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC J01DH02
ATC J01DH52
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Meropenem
Additional database identifiers
Drugs Product Database (DPD)
41
ChemSpider
389924
BindingDB
50129062
PDB
MEM
ZINC
ZINC000003808779
GenBank Gene Database
X59460
GenBank Protein Database
41216
UniProt Accession
DACB_ECOLI
GenBank Gene Database
U37105
GenBank Protein Database
1019897
UniProt Accession
BLO10_PSEAI
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3002
GenAtlas
DPEP1
GeneCards
DPEP1
GenBank Gene Database
D13137
GenBank Protein Database
219600
UniProt Accession
DPEP1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72